PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21334870-0	2012	Lycopene inhibits the proliferation of androgen-dependent human prostate tumor cells through activation of PPARgamma-LXRalpha-ABCA1 pathway.	Lycopene	0-8	ATP binding cassette subfamily A member 1	Homo sapiens	126-131	
22137263-0	2012	Lycopene and the LXRalpha agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPARgamma-LXRalpha-ABCA1 pathway.	Lycopene	0-8	ATP binding cassette subfamily A member 1	Homo sapiens	158-163	
22137263-1	2012	In our previous study, we demonstrated that lycopene can inhibit the proliferation of androgen-dependent prostate LNCaP cancer cells through the activation of the peroxisome proliferator-activated receptor gamma (PPARgamma)-liver X receptor alpha (LXRalpha)-ATP-binding cassette transporter 1 (ABCA1) pathway.	Lycopene	44-52	ATP binding cassette subfamily A member 1	Homo sapiens	294-299	
22137263-4	2012	We show that lycopene significantly increased protein and mRNA expression of PPARgamma, LXRalpha and ABCA1 and cholesterol efflux (i.e., decreased cellular cholesterol and increased cholesterol in culture medium).	Lycopene	13-21	ATP binding cassette subfamily A member 1	Homo sapiens	101-106	
22137263-7	2012	Furthermore, lycopene in combination with the LXRalpha agonist T0901317 exhibited synergistic effects on cell proliferation and protein expression of PPARgamma, LXRalpha and ABCA1.	Lycopene	13-21	ATP binding cassette subfamily A member 1	Homo sapiens	174-179	
22137263-8	2012	These results demonstrate that lycopene can inhibit DU145 cell proliferation via PPARgamma-LXRalpha-ABCA1 pathway and that lycopene and T0901317 exhibit synergistic effects.	Lycopene	31-39	ATP binding cassette subfamily A member 1	Homo sapiens	100-105	
21334870-5	2012	The present study is the first to demonstrate that the anti-proliferative effect of lycopene on LNCaP cells involves the activation of the PPARgamma-LXRalpha-ABCA1 pathway, leading to reduced cellular total cholesterol levels.	Lycopene	84-92	ATP binding cassette subfamily A member 1	Homo sapiens	158-163	
21208793-6	2011	Concomitant addition of lycopene and the PPARgamma inhibitor GW9662 or lycopene and mevalonate blocked the carotenoid-induced increase in ABCA1 and cav-1 expressions.	Lycopene	24-32	ATP binding cassette subfamily A member 1	Homo sapiens	138-143	
21208793-6	2011	Concomitant addition of lycopene and the PPARgamma inhibitor GW9662 or lycopene and mevalonate blocked the carotenoid-induced increase in ABCA1 and cav-1 expressions.	Lycopene	71-79	ATP binding cassette subfamily A member 1	Homo sapiens	138-143	
21208793-7	2011	These results imply a potential role of lycopene in attenuating foam cell formation and, therefore, in preventing atherosclerosis by a cascade mechanism involving inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase, RhoA inactivation and subsequent increase in PPARgamma and liver X receptor alpha activities and enhancement of ABCA1 and cav-1 expressions.	Lycopene	40-48	ATP binding cassette subfamily A member 1	Homo sapiens	338-343